Related Experiment Video
Updated: Dec 6, 2025

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models
Published on: April 19, 2024
Filter clotting with continuous renal replacement therapy in COVID-19
Paul Endres1, Rachel Rosovsky2, Sophia Zhao1
1Division of Nephrology, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, GRB 1008, Boston, MA, 02114, USA.
High rates of filter clotting occur in critically ill COVID-19 patients undergoing continuous renal replacement therapy (CRRT). An anticoagulation protocol using anti-factor Xa levels for heparin dosing showed promise in reducing later filter loss.
Area of Science:
- Nephrology
- Critical Care Medicine
- Hematology
Background:
- Coronavirus disease 2019 (COVID-19) is linked to thromboembolic events.
- Hemostatic abnormalities in COVID-19 may cause filter clotting during continuous renal replacement therapy (CRRT).
Purpose of the Study:
- To assess the frequency of CRRT filter clotting in COVID-19 patients.
- To evaluate a CRRT anticoagulation protocol using anti-factor Xa levels for heparin dosing.
Main Methods:
- Multi-center study of COVID-19 patients receiving CRRT.
- Compared outcomes between an anti-factor Xa guided heparin protocol and standard care.
- Primary outcome: CRRT filter loss.
Main Results:
- 83% of patients lost at least one CRRT filter.
- No significant difference in first or second filter loss between groups.
- The anti-factor Xa protocol group had less third filter loss (55% vs. 93%) and longer third filter survival.
Conclusions:
- CRRT filter loss is a significant issue in COVID-19 patients.
- An anticoagulation protocol guided by anti-factor Xa levels is a viable approach for heparin dosing in this population.
Related Concept Videos
Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury II: Pathophysiology

